# Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

> **NCT00831766** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 51 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Lenalidomide (Revlimid®)

## Key facts

- **NCT ID:** NCT00831766
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-25
- **Primary completion:** 2015-02-17
- **Final completion:** 2020-11-16
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831766, "Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00831766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*